Last updated: May 29, 2026
Restasis Multidose (Cyclosporine Ophthalmic Emulsion) Suppliers: What Companies Manufacture and Supply the Product and Drug Substance?
Restasis Multidose is an ophthalmic cyclosporine formulation supplied in unit-dose containers. Supplier coverage across finished product and upstream components depends on the specific supply chain role (drug substance, sterile fill-finish, packaging, and distribution).
No sufficient, citable supplier-identification data (named entities tied to Restasis Multidose manufacturing, drug substance sourcing, or Orange Book/CMC-linked supplier disclosures) was provided to produce a complete, accurate supplier list.
Who supplies Restasis Multidose in the US?
Restasis is marketed by AbbVie. Finished-dose manufacturing and upstream sourcing are typically documented via FDA drug application manufacturing site disclosures, FDA facility listings, and label “Manufactured for”/“Distributed by” statements. Those named supplier entities are not included in the available inputs.
Is AbbVie the supplier or the marketer of Restasis Multidose?
AbbVie is the US brand owner/marketer for Restasis. Supplier identification for manufacture and distribution requires the product’s label imprint and FDA manufacturing-site data, which are not provided.
Which companies do sterile fill-finish for ophthalmic cyclosporine unit-dose emulsions?
Fill-finish supplier identification requires FDA manufacturing-site records for the specific dosage form (multidose or unit-dose) and strength, which are not included.
What suppliers provide cyclosporine for Restasis Multidose?
Cyclosporine drug substance sourcing is specific to the drug application and manufacturer of record. Without the drug master file (DMF) linkages or API manufacturer disclosure tied to the Restasis Multidose application, named upstream suppliers cannot be stated.
Are cyclosporine suppliers different for Restasis vs Restasis Multidose?
They can be, depending on formulation tech transfer, approved manufacturing sites, and DMF cross-references. This cannot be determined from the provided information.
What manufacturers make Restasis Multidose’s sterile emulsion and fill the packaging?
For ophthalmic emulsions, the manufacturing chain includes sterile compounding, emulsification/homogenization, sterile filtration (if applicable), aseptic filling, in-process controls, and container-closure validation. Named suppliers require the listed manufacturing sites on the FDA-approved labeling and/or inspections tied to the application.
Does Restasis Multidose use a specific container-closure supplier?
Container and closure components (dropper/nozzle, unit-dose or multidose reservoir components, sealing systems) are often sourced from specialized suppliers. Named component suppliers require label component statements or supplier qualification disclosures not provided.
What does the Orange Book or FDA labeling say about Restasis Multidose suppliers?
Orange Book entries can list the listed drug and patent-covered application, but the Orange Book does not reliably enumerate all CMC suppliers for finished product or API. FDA labeling typically lists “Manufactured for” or “Distributed by,” but those label details are not included.
Where do suppliers show up on the Restasis Multidose label?
In practice: the label may name the manufacturer, packager, distributor, and local rep. The exact printed entities must be extracted from the specific product label for Restasis Multidose, which is not present in the input.
Which supply-chain contracts matter for Restasis Multidose continuity of supply?
Continuity risk in ophthalmic sterile products is tied to:
- sterile manufacturing capacity and aseptic processing lines
- container-closure supply stability
- quality/regulatory history of manufacturing sites
- cold-chain or stability requirements for the specific emulsion system
Named contract counterparties depend on procurement disclosures, supplier qualification lists, or inspection histories, none of which are provided.
What generic or biosimilar supplier landscape affects Restasis Multidose supply?
Restasis is not a biologic; it is a small-molecule ophthalmic drug. Competitive supply from generics is driven by FDA-approved ANDA products and their manufacturers. Supplier mapping requires the ANDA product list and labeling manufacturer details for each generic, none of which are provided.
How does Restasis Multidose procurement work for wholesalers and distributors?
Wholesaler distribution is generally handled by standard pharmaceutical distribution networks. Identifying the named distributor-of-record for this specific SKU requires the label distribution statement and/or NDC-level distributor listing, which is not included.
Key Takeaways
- Restasis Multidose is marketed by AbbVie, but named upstream and manufacturing suppliers cannot be identified from the provided inputs.
- Supplier identification requires CMC-linked manufacturing-site and label “manufactured for”/“distributed by” entities tied to the Restasis Multidose dosage form and strength.
- No citable supplier roster can be produced without those label and regulatory record inputs.
FAQs
- Who is the manufacturer of Restasis Multidose on the package label?
- Which company supplies the cyclosporine active pharmaceutical ingredient (API) for Restasis Multidose?
- What sterile manufacturing and fill-finish sites are approved for Restasis Multidose?
- Do Restasis and Restasis Multidose use the same manufacturing supplier and container-closure components?
- Which distributors carry Restasis Multidose at the NDC level in the US?
References
- (No sources were provided in the prompt, and no citable FDA/label/Orange Book records were included to support supplier-identification claims.)
